Myasthenia gravis. Update on diagnosis and therapy

被引：8

作者：

Estevez, Daniel Apolinar Garcia ^{[1
,2
]}

Fernandez, Julio Pardo ^{[3
]}

机构：

[1] Complexo Hosp Univ Ourense, Serv Neurol, Orense, Spain

[2] Inst Invest Sanitarias Galicia Sur, Grp Invest Neurociencias Clin, SERGAS UVIGO, Vigo, Pontevedra, Spain

[3] Univ Santiago De Compostela, Complexo Hosp Univ Santiago De Compostela, Fac Med, Serv Neurol,Unidad Enfermedades Neuromusculares, Santiago De Compostela, A Coruna, Spain

来源：

MEDICINA CLINICA | 2023年 / 161卷 / 03期

关键词：

Myasthenia gravis; Autoantibodies; Thymus; Acetylcholine receptor; Neuromuscular junction; Immunotherapy; INTERNATIONAL CONSENSUS GUIDANCE; CLINICAL-FEATURES; DOUBLE-BLIND; ANTIBODY; CLASSIFICATION; MANAGEMENT; GUIDELINES; EFFICACY; SAFETY; ADULTS;

D O I：

10.1016/j.medcli.2023.04.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myasthenia gravis is an autoimmune disease caused by the presence of specific antibodies targeting different postsynaptic components of the neuromuscular junction, and is clinically characterized by the presence of fatigueable muscle weakness. In the etiopathogenesis plays a central role the thymus and the most frequently detected pathogenic autoantibodies are targeted to the acetylcholine recep-tor. The increase in the knowledge of the immunological components of the neuromuscular junction in the last two decades has been fundamental to identify new pathogenic antibodies, reduce the percen-tage of patients with seronegative myasthenia, and propose a classification of patients into subgroups with clinical-therapeutic interest. In addition, in recent years, new drugs have been developed for the treatment of patients with myasthenia gravis that are refractory to conventional immunosuppressive treatment.& COPY; 2023 Elsevier Espan & SIM;a, S.L.U. All rights reserved.

引用

页码：119 / 127

页数：9